Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

@article{Heile2000EvaluationOH,
  title={Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.},
  author={J M Heile and Y L Fong and Domenico Rosa and Kim Berger and Giulietta Saletti and Susanna Campagnoli and Giuliano Bensi and Sabrina Capo and Stephen A. Coates and Kevin R Crawford and Christine Yang Dong and Mark Wininger and Gary Baker and L C Cousens and David M Chien and Philip Ng and P Archangel and Guido Grandi and Michael Houghton and Sergio Abrignani},
  journal={Journal of virology},
  year={2000},
  volume={74 15},
  pages={
          6885-92
        }
}

• J M Heile, Y L Fong, +17 authors Sergio Abrignani
• Published 2000 in Journal of virology

Hepatitis C virus (HCV) is the leading causative agent of blood-borne chronic hepatitis and is the target of intensive vaccine research. The virus genome encodes a number of structural and nonstructural antigens which could be used in a subunit vaccine. The HCV envelope glycoprotein E2 has recently been shown to bind CD81 on human cells and therefore is a prime candidate for inclusion in any such vaccine. The experiments presented here assessed the optimal form of HCV E2 antigen from the… CONTINUE READING

Save to Library

Create Alert

Cite

View Paper